A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: Modafinil, levodopa-carbidopa, naltrexone

Drug and Alcohol Dependence

Volumn 136, Issue 1, 2014, Pages 100-107

  Schmitz, Joy M ^a   Green, Charles E ^b   Stotts, Angela L ^b   Lindsay, Jan A ^c,d,e   Rathnayaka, Nuvan S ^a   Grabowski, John ^f   Moeller, F Gerard ^g  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Education and Clinical Center   (United States)

^e Houston VA Health Services Research and Development Center of Excellence   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cocaine cessation; Contingency management; Levodopa; Modafinil; Naltrexone; Relapse prevention

Indexed keywords

COCAINE CESSATION; CONTINGENCY MANAGEMENT; LEVODOPA; MODAFINIL; NALTREXONE; RELAPSE PREVENTION;

ADOLESCENT; ADULT; BENZHYDRYL COMPOUNDS; CARBIDOPA; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; DATA INTERPRETATION, STATISTICAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; NALTREXONE; NARCOTIC ANTAGONISTS; NEUROPSYCHOLOGICAL TESTS; PATIENT COMPLIANCE; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893716534     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.12.015     Document Type: Article

References (45)

1. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., Smith E.V., Kahn R., Chiang N., Vocci F., Ciraulo D., Dackis C., Roache J.D., Salloum I.M., Somoza E., Urschel H.C., Elkashef A.M. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009, 104:133-139.
2. Berger S.P., Winhusen T.M., Somoza E.C., Harrer J.M., Mezinskis J.P., Leiderman D.B., Montgomery M.A., Goldsmith R.J., Bloch D.A., Singal B.M., Elkashef A. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 2005, 100(Suppl. 1):58-67.
3. Bisaga A., Aharonovich E., Cheng W.Y., Levin F.R., Mariani J.J., Raby W.N., Nunes E.V. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend. 2010, 111:97-104.
4. Bisaga A., Aharonovich E., Garawi F., Levin F.R., Rubin E., Raby W.N., Nunes E.V. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend. 2006, 81:267-274.
5. Bisaga A., Aharonovich E., Garawi F., Levin F.R., Rubin E., Raby W.N., Vosburg S.K., Nunes E.V. Utility of lead-in period in cocaine dependence pharmacotherapy trials. Drug Alcohol Depend. 2005, 77:7-11.
6. Bisaga A., Sullivan M.A., Cheng W.Y., Carpenter K.M., Mariani J.J., Levin F.R., Raby W.N., Nunes E.V. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend. 2011, 119:e23-e29.
7. Collins L.M., Schafer J.L., Kam C.M. A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol. Methods 2001, 6:330-351.
8. Corrigall W.A., Coen K.M. Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology (Berl.) 1991, 104:167-170.
9. Crits-Christoph P., Gallop R., Gibbons M.B.C., Sadicario J.S., Woody G. Measuring outcome in the treatment of cocaine dependence. J. Alcohol. Drug Depend. 2013, 1:1-8.
10. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
11. Dackis C.A., Kampman K.M., Lynch K.G., Plebani J.G., Pettinati H.M., Sparkman T., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J. Subst. Abuse Treat. 2012, 43:303-312.
12. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., Rowan A., Poole S., White L., O'Brien C.P. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 2003, 70:29-37.
13. Dallery J., Silverman K., Chutuape M.A., Bigelow G.E., Stitzer M.L. Voucher-based reinforcement of opiate plus cocaine abstinence in treatment-resistant methadone patients: effects of reinforcer magnitude. Exp. Clin. Psychopharmacol. 2001, 9:317-325.
14. Del Boca F.K., Kranzler H.R., Brown J., Korner P.F. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol. Clin. Exp. Res. 1996, 20:1412-1417.
15. Applied Missing Data Analysis (Methodology in the Social Sciences) 2010, Guilford Press, New York. C. Enders (Ed.).
16. FDA Guidance for industry. Enrichment strategies for clinical trials to support approval of human drugs and biological products. 2013, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf (accessed January 2013).
17. First M.B., Pincus H.A. The DSM-IV Text Revision: rationale and potential impact on clinical practice. Psychiatr. Serv. 2002, 53:288-292.
18. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
19. Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence 1992, DHHS, Rockville, MD. R.M. Kadden, K. Carroll, D. Donovan, N. Cooney, P. Monti, D. Abrams, M. Litt, R. Hester (Eds.).
20. Kampman K.M., Leiderman D., Holmes T., LoCastro J., Bloch D.A., Reid M.S., Shoptaw S., Montgomery M.A., Winhusen T.M., Somoza E.C., Ciraulo D.A., Elkashef A., Vocci F. Cocaine Rapid Efficacy Screening Trials (CREST): lessons learned. Addiction 2005, 100(Suppl. 1):102-110.
21. Katz E.C., Robles-Sotelo E., Correia C.J., Silverman K., Stitzer M.L., Bigelow G. The brief abstinence test: effects of continued incentive availability on cocaine abstinence. Exp. Clin. Psychopharmacol. 2002, 10:10-17.
22. Koob G.F. Hedonic homeostatic dysregulation as a driver of drug-seeking behavior. Drug Discov. Today Dis. Models 2008, 5:207-215.
23. Koob G.F., Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2008, 363:3113-3123.
24. Larimer M.E., Palmer R.S., Marlatt G.A. Relapse prevention. An overview of Marlatt's cognitive-behavioral model. Alcohol Res. Health 1999, 23:151-160.
25. Malcolm R., Swayngim K., Donovan J.L., DeVane C.L., Elkashef A., Chiang N., Khan R., Mojsiak J., Myrick D.L., Hedden S., Cochran K., Woolson R.F. Modafinil and cocaine interactions. Am. J. Drug Alcohol Abuse 2006, 32:577-587.
26. Martinez D., Carpenter K.M., Liu F., Slifstein M., Broft A., Friedman A.C., Kumar D., Van Heertum R., Kleber H.D., Nunes E. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am. J. Psychiatry 2011, 168:634-641.
27. McCann D.J., Li S.H. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci. Ther. 2012, 18:414-418.
28. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. The Fifth Edition of the Addiction Severity Index. J. Subst. Abuse Treat. 1992, 9:199-213.
29. Mereu M., Bonci A., Newman A.H., Tanda G. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology (Berl.) 2013, 229:415-434.
30. Mooney M.E., Sayre S.L., Green C., Rhoades H., Schmitz J.M. Comparing measures of medication taking in a pharmacotherapy trial for cocaine dependence. Addict. Disord. Treat. 2004, 3:165-173.
31. Mooney M.E., Schmitz J.M., Moeller F.G., Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend. 2007, 88:214-223.
32. Pettinati H.M., Kampman K.M., Lynch K.G., Xie H., Dackis C., Rabinowitz A.R., O'Brien C.P. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict. Behav. 2008, 33:651-667.
33. Ramsey N.F., van Ree J.M. Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 1991, 40:807-810.
34. Sayre S.L., Evans M., Hokanson P.S., Schmitz J.M., Stotts A.L., Averill P., Grabowski J. Who gets in? Recruitment and screening processes of outpatient substance abuse trials. Addict. Behav. 2004, 29:389-398.
35. Schmitz J.M., Lindsay J.A., Green C.E., Herin D.V., Stotts A.L., Moeller F.G. High-dose naltrexone therapy for cocaine-alcohol dependence. Am. J. Addict. 2009, 18:356-362.
36. Schmitz J.M., Lindsay J.A., Stotts A.L., Green C.E., Moeller F.G. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp. Clin. Psychopharmacol. 2010, 18:238-244.
37. Schmitz J.M., Mooney M.E., Moeller F.G., Stotts A.L., Green C., Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008, 94:142-150.
38. Schmitz J.M., Rathnayaka N., Green C.E., Moeller F.G., Dougherty A.E., Grabowski J. Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Front. Psychiatry 2012, 3:77.
39. Schmitz J.M., Stotts A.L., Rhoades H.M., Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict. Behav. 2001, 26:167-180.
40. Schmitz J.M., Stotts A.L., Sayre S.L., DeLaune K.A., Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am. J. Addict. 2004, 13:333-341.
41. Shoptaw S., Watson D.W., Reiber C., Rawson R.A., Montgomery M.A., Majewska M.D., Ling W. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 2005, 100(Suppl. 1):78-90.
42. Silverman K., Chutuape M.A., Bigelow G.E., Stitzer M.L. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology (Berl.) 1999, 146:128-138.
43. Sofuoglu M., DeVito E.E., Waters A.J., Carroll K.M. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 2013, 64:452-463.
44. Stotts A.L., Schmitz J.M., Rhoades H.M., Grabowski J. Motivational interviewing with cocaine-dependent patients: a pilot study. J. Consult. Clin. Psychol. 2001, 69:858-862.
45. Mixed Effects Models and Extensions in Ecology with R 2009, Springer, New York. A.F. Zuur, E.N. Leno, N. Walker, A.A. Saveliev, G.M. Smith (Eds.).